clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Fractures, Open D005597 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Cysts D003560 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Confusion D003221 4 associated lipids
Prurigo D011536 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Duodenitis D004382 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Nilius AM et al. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. 2001 Antimicrob. Agents Chemother. pmid:11408246
Giacometti A et al. In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 2005 Antimicrob. Agents Chemother. pmid:16127075
Peric M et al. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. 2003 Antimicrob. Agents Chemother. pmid:12604536
Watanabe K et al. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. 2004 Antimicrob. Agents Chemother. pmid:15561829
Odenholt-Tornqvist I et al. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. 1995 Antimicrob. Agents Chemother. pmid:7695310
Kim JM et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. 2004 Antimicrob. Agents Chemother. pmid:15561865
Rodvold KA et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. 1997 Antimicrob. Agents Chemother. pmid:9174209
Bax HI et al. Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. 2016 Antimicrob. Agents Chemother. pmid:26883697
Aziz DB et al. Rifabutin Is Active against Mycobacterium abscessus Complex. 2017 Antimicrob. Agents Chemother. pmid:28396540
Wang G et al. Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. 1999 Antimicrob. Agents Chemother. pmid:10049289
Tomioka H et al. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. 1999 Antimicrob. Agents Chemother. pmid:10582897
Roblin PM et al. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. 2010 Antimicrob. Agents Chemother. pmid:20038627
Chang HR and Pechère JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2837140
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Perronne C et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. 1990 Antimicrob. Agents Chemother. pmid:2171421
Goldstein EJ et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. 1999 Antimicrob. Agents Chemother. pmid:10543769
Inderlied CB et al. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. 1994 Antimicrob. Agents Chemother. pmid:7986017
Gorzynski EA et al. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. 1989 Antimicrob. Agents Chemother. pmid:2524998
Meier A et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. 1994 Antimicrob. Agents Chemother. pmid:8192472
Kohno Y et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. 1990 Antimicrob. Agents Chemother. pmid:2140497
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Chan GP et al. Clinical trial of clarithromycin for lepromatous leprosy. 1994 Antimicrob. Agents Chemother. pmid:8203847
Onyeji CO et al. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. 1994 Antimicrob. Agents Chemother. pmid:8203849
Clark C et al. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. 2002 Antimicrob. Agents Chemother. pmid:12183253
Osborne CS et al. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. 2009 Antimicrob. Agents Chemother. pmid:19596876
Tateda K et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891128
Hunt Gerardo S et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. 1996 Antimicrob. Agents Chemother. pmid:8891154
Kanamaru T et al. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. 2001 Antimicrob. Agents Chemother. pmid:11502514
Lemaire S et al. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. 2009 Antimicrob. Agents Chemother. pmid:19564365
Steele-Moore L et al. In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. 1999 Antimicrob. Agents Chemother. pmid:10383373
Fernandes PB et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. 1989 Antimicrob. Agents Chemother. pmid:2530933
Alvarez A et al. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. 2009 Antimicrob. Agents Chemother. pmid:19546360
Koh WJ et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. 2013 Antimicrob. Agents Chemother. pmid:23478956
Zhou Z et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. 2015 Antimicrob. Agents Chemother. pmid:25451048
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Hogan PA and Sheehan DJ Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. 1998 Antimicrob. Agents Chemother. pmid:9835536
Diacon AH et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. 2012 Antimicrob. Agents Chemother. pmid:22391540
Cirioni O et al. Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. 2008 Antimicrob. Agents Chemother. pmid:18779356
Tomioka H et al. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. 1993 Antimicrob. Agents Chemother. pmid:8431020
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Cynamon MH et al. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. 2000 Antimicrob. Agents Chemother. pmid:10991883
Fong IW et al. Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. 2002 Antimicrob. Agents Chemother. pmid:12121899
Pryjma M et al. Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. 2017 Antimicrob. Agents Chemother. pmid:28874379
Bolhuis MS et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. 2013 Antimicrob. Agents Chemother. pmid:23689722
Spaniol V et al. Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. 2015 Antimicrob. Agents Chemother. pmid:25583725
Horgen L et al. Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. 1998 Antimicrob. Agents Chemother. pmid:9797242
Bermudez LE et al. Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7695252
Conte JE et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. 1995 Antimicrob. Agents Chemother. pmid:7726492
Nagai K et al. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. 2001 Antimicrob. Agents Chemother. pmid:11600391
Klemens SP and Cynamon MH Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7986001
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Berry V et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. 1998 Antimicrob. Agents Chemother. pmid:9835514
Furuie H et al. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. 2010 Antimicrob. Agents Chemother. pmid:19933801
Friedman ND et al. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. 2016 Antimicrob. Agents Chemother. pmid:26883709
Chu SY et al. Absolute bioavailability of clarithromycin after oral administration in humans. 1992 Antimicrob. Agents Chemother. pmid:1387301
Yajko DM et al. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. 1992 Antimicrob. Agents Chemother. pmid:1387302
de Lalla F et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. 1992 Antimicrob. Agents Chemother. pmid:1387303
Zhanel GG et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. 2008 Antimicrob. Agents Chemother. pmid:18285482
Luna-Herrera J et al. Antituberculosis activity of clarithromycin. 1995 Antimicrob. Agents Chemother. pmid:8593004
Ellis LC et al. Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. 1995 Antimicrob. Agents Chemother. pmid:8593025
Truffot-Pernot C et al. Clarithromycin is inactive against Mycobacterium tuberculosis. 1995 Antimicrob. Agents Chemother. pmid:8593032
Naik S and Ruck R In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. 1989 Antimicrob. Agents Chemother. pmid:2817858
Collins LA et al. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. 1998 Antimicrob. Agents Chemother. pmid:9527783
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Klis S et al. Compliance with antimicrobial therapy for buruli ulcer. 2014 Antimicrob. Agents Chemother. pmid:25225342
Tsay FW et al. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. 2017 Antimicrob. Agents Chemother. pmid:28807915
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Portaels F et al. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9687409
Vaara M et al. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. 2010 Antimicrob. Agents Chemother. pmid:20479195
Andini N and Nash KA Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. 2006 Antimicrob. Agents Chemother. pmid:16801446
Heifets LB et al. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. 1992 Antimicrob. Agents Chemother. pmid:1416852
Brown BA et al. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. 1992 Antimicrob. Agents Chemother. pmid:1416891
Bermudez LE et al. Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. 2000 Antimicrob. Agents Chemother. pmid:10991834
Biehle J and Cavalieri SJ In vitro susceptibility of Mycobacterium kansasii to clarithromycin. 1992 Antimicrob. Agents Chemother. pmid:1416897
Chu SY et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. 1992 Antimicrob. Agents Chemother. pmid:1489187
Wang G et al. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. 2001 Antimicrob. Agents Chemother. pmid:11181351
Rastogi N et al. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. 2000 Antimicrob. Agents Chemother. pmid:10991870
Araujo FG et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1489188
Gan VN et al. Pharmacokinetics of a clarithromycin suspension in infants and children. 1992 Antimicrob. Agents Chemother. pmid:1489191
Finch R et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. 2002 Antimicrob. Agents Chemother. pmid:12019085
Prazeres Magalhães P et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. 2002 Antimicrob. Agents Chemother. pmid:12019131
Mougari F et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. 2017 Antimicrob. Agents Chemother. pmid:27799212
Kutlin A et al. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. 2002 Antimicrob. Agents Chemother. pmid:11796350
Nash KA Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. 2001 Antimicrob. Agents Chemother. pmid:11353601
Jacks SS et al. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. 2003 Antimicrob. Agents Chemother. pmid:12709351
Mor N and Esfandiari A Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. 1997 Antimicrob. Agents Chemother. pmid:9303411
Alffenaar JW et al. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. 2010 Antimicrob. Agents Chemother. pmid:20585115
Kishii K et al. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. 2010 Antimicrob. Agents Chemother. pmid:20585130
Hoffman HL et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. 2003 Antimicrob. Agents Chemother. pmid:12543686
Polis MA et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. 1997 Antimicrob. Agents Chemother. pmid:9257746
Lounis N et al. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. 2001 Antimicrob. Agents Chemother. pmid:11600387
Weiss S et al. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. 2015 Antimicrob. Agents Chemother. pmid:26392505
Gikas A et al. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. 2001 Antimicrob. Agents Chemother. pmid:11600400
Ji B et al. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. 1994 Antimicrob. Agents Chemother. pmid:7872741
Skinner PS et al. A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. 1994 Antimicrob. Agents Chemother. pmid:7872747
Valero G et al. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. 1994 Antimicrob. Agents Chemother. pmid:7872769
Piccolomini R et al. Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. 1998 Antimicrob. Agents Chemother. pmid:9797240
Patel KB et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891147